Sažetak
Uvod/Cilj. Acetilholinesteraza (AChE) i butirilholinesteraza (BuChe) su važni biomarkeri ekspozicije organofosfornim i karbamatnim insekticidima. S obzirom na to da procena nivoa inhibicije holinesteraze, koja odgovara težini trovanja ovim agensima, zavisi od normalnih vrednosti, koje mogu varirati u različitim populacijama, bilo je važno odrediti ih u našoj populaciji, što do sada nije urađeno. Stoga je cilj ovog rada bio da se odrede referentne vrednosti za aktivnost AChE i BuChE u zdravoj populaciji odraslih osoba na području Republike Srbije. Metode. Aktivnost AChE u eritrocitima merena je spekrofotometrijski (λ = 412 nm). Korišćena je modifikovana Ellman-ova metoda. Aktivnost BuChE u plazmi određivana je na integrisanom hemijskom sistemu (Dimenzion RxLMax) sa gotovim reagens uloškom za analizu. Ispitanici su bili dobrovoljni davaoci krvi iz Instituta za transfuziologiju i hemobiologiju Vojnomedicinske akademije. Za obradu podataka korišćen je SPSS (Statistical Package for Social Sciences) softverski program. Rezultati. U grupi od 851 osobe bilo je 728 muškaraca i 123 žene. Srednje životno doba ispitanika bilo je 39,1 ± 11,6 godina. Za sve ispitanike određena je aktivnost AChE, dok je aktivnost butirilholinesteraze određena kod 205 ispitanika (169 muškaraca i 36 žena). Srednja vrednost aktivnosti acetilholinesteraze iznosila je 8 090,6 ± 1 976,7 IJ/L, a za butirilholinesterazu 14 556.6 ± 4 078,1 U/L. Odsustvo normalne distribucije podataka kod muškaraca uslovilo je da referentne vrednosti enzima odredimo kao 2,5-ti i 97,5-ti percentil. Zaključak. Rezultati ove pilot studije o aktivnosti holinesteraza u zdravoj populaciji u Republici Srbiji, koja je sada urađena prvi put, ukazuju na potrebu da se pri proceni težine trovanja uzmu u obzir širi rasponi aktivnosti holinesteraza. Preporučuje se proširivanje studije za BuChE, sa uključenjem većeg broja ispitanika ženskog pola i podataka o telesnoj masi, u cilju dobijanja preciznijih referentnih vrednosti.
Ključne reči
||holinesteraze
butyrylcholinesterases||
||butirilholinesteraze
cholinesterase inhibitors||
||holinesteraza
inhibitori
insecticides||
||insekticidi
poisoning||
||trovanje
reference values||
||referentne vrednosti
serbia||
||srbija
Reference
Bosak A, Katalinić M, Kovarik Z. Cholinesterases: structure, role, and inhibition. Arh Hig Rada Toksikol 2011; 62(2): 175−90. (Serbian)
Whittaker VP. How the cholinesterases got their modern names. Chem Biol Interact 2010; 187(1−3): 23−6.
Holmstedt B. Cholinesterase inhibitors: An introduction. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibi-tors. London: Martin Dunitz Ltd; 2000. p. 1−8.
Čolović M, Krstić D, Lazarević-Pašti T, Bondžić A, Vasić V. Ace-tylcholinesterase inhibitors. Pharmacology and Toxicology. Curr Neuropharmacol 2013; 11(3): 315−35.
Pohanka M. Cholinesterases, a Target of pharmacology and toxicology. Biomed Pap 2011; 155(3): 219−30.
Chen X, Fang L, Liu J, Zhan C. Reaction pathway and free energy profile for butyrylcholinesterase-catalyzed hydrolysis of acetylcholine. J Phys Chem B 2011; 115(5): 1315−22.
Davis L, Britten JJ, Morgan M. Cholinesterase Its significance in anaesthetic practice. Anaesthesia 1997; 52(3): 244−60.
Santarpia L, Grandone I, Contaldo F, Pasanisi F. Butyrylcholines-terase as a prognostic marker: A review of the literature. J Ca-chexia Sarcopenia Muscle 2013; 4(1): 31−9.
Soliday FK, Conley YP, Henker R. Pseudocholinesterase deficien-cy: a comprehensive review of genetic, acquired, and drug in-fluences. AANA J 2010; 78(4): 313−20.
Johnell K, Fastbom J. Concurrent use of anticholinergic drugs and cholinesterase inhibitors: Register-based study of over 700, 000 elderly patients. Drugs Aging 2008; 25(10): 871−7.
Karalliedde L, Henry J. The acute cholinergic syndrome. In: Karraliedde L, Feldman S, Henry J, Marrs T, editors. Organophosphates and health. London: Imperial College Press; 2001. p. 109−40.
Brock A, Brock V. Factors affecting inter-individual variation in human plasma cholinesterase activity: body weight, height, sex, genetic polymorphism and age. Arch Environ Contam Toxicol 1993; 24(1): 93−9.
Christenson WR, van Goethem DL, Schroeder RS, Wahle RS, Dass PD, Sangha GK, et al. Interlaboratory cholinesterase determina-tions and the effect on the results of statistical evaluation of cholinesterase inhibition. Toxicol Lett 1994; 71(2): 139−50.
Trundle D, Marcial G. Detection of Cholinesterase Inhibition. The significance of Cholinesterase Measurements. Ann Clin Lab Sci 1988; 18(5): 345−52.
Elman G, Courtney D, Andres V, Featherstone R. A new and rapid colorimetric determination of acetylcholinesterase activity. Bi-ochem Pharmacol 1961; 7: 88−9.
Reiner E, Šinko G, Škrinjarić-Špoljar M, Simeon-Rudolf V. Com-parison of protocols for measuring activities of human blood cholinesterases by the Ellman method. Arch Hig Rada Toksi-kol 2000; 51: 13−8.
Aldridge WN, Davies DR. Determination of cholinesterase ac-tivity in human blood. BMJ 1952; 1(4765): 945–7.
Worek F, Mast U, Kiderlen D, Diepold C, Eyer P. Improved de-termination of acetylcholinesterase activity in human whole blood". Clin Chim Acta 1999; 288(1-2): 73−90.
Gal EM, Roth E. Spectrophotometric methods for determina-tion of cholinesterase activity. Clin Chim Acta 1957; 2(4): 316–26.
Sánchez LH, Medina OM, Gómez G, González CI, Flórez-Vargas Ó. Laboratory genetic-based reference values for cholinesterase activity in a Colombian population: A step forward in per-sonalized diagnostics. Biomedica 2015; 35 Spec: 20−9.
Lepage L, Schiele F, Gueguen R, Slest G. Total Cholinesterase in Plasma: Biological Variations and Reference Limits. Clin Chem 1985;31(4): 546-550.
Chan L, Balabaskaran S, Delilkan AE, Ong LH. Blood cholines-terase levels in a group of Malaysian blood donors. Malays J Pathol 1994; 16(2): 161−4.
Abdullat EM, Obeidat NM, Al-Jaghbir MT, Al-Hiari YM, Al-Hadidi K. Establishing the Cholinesterase Levels in Jordan: An Investigation and Monitoring Model for Pesticide Outbreak. Med J 2015; 49(3): 129−38.
Westgard JO, Hund MR, Lahmeyer BL. Estimates of Normal Ranges for 15 Determinations on the Du Pont Pont Automat-ic Clinical Analyzer. Madison, WI: Dept. of Medicine and Clin-ical Laboratories, University of Wisconsin Center for Health Science; 2003.
Sunderman FW Jr. Current concepts of "normal values," "refer-ence values," and "discrimination values," in clinical chemistry. Clin Chem 1975; 21(13): 1873−7.
Solberg HE. The IFCC recommendation on estimation of ref-erence intervals. The Ref Val Program. Clin Chem Lab Med 2004; 42(7): 710–714.
Harris EK, Boyd JC. On dividing reference data in to subgroups to produce separate reference ranges. Clin Chem 1990; 36(2): 265−70.
Horowitz GL, Altaie CS, Boyd JC, Ceriotti F, Garg U, Horn P. Defining, Establishing, and Ver ifying Reference Intervals in the Clinical Laboratory; Approved Guideline. 3rd ed. Wayne, PA: CLSI; 2008.
Guidi GC, Salvagno GL. Reference intervals as a tool for total quality management. Biochem Med 2010; 20(2): 165−72.
Brock A, Brock V. Plasma cholinesterase activity in a healthy population group with no occupational exposure to known cholinesterase inhibitors: Rrelative influence of some factors related to normal inter- and intra-individual variations. Scand J Clin Lab Invest 1990; 50(4): 401−8.
Mayo Medical Laboratories. Pseudocholinesterase, Total, Se-rum. U.S.: Mayo Clinic. Available from: http://www.mayomedicallaboratories.com/testcatalog/Clinical+and+Interpretive/8
Test name (Cholinesterase, Serum, Plasma, RBC). U.S.: Quest Diagnostics clinical laboratory. Available from: http://www.questdiagnostics.com/testcenter/TestDetail.action?ntc=39481
Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnosis.St. Louis: W. B. Saunders Company; 2012.